New treatment strategies in childhood acute lymphoblastic leukaemia
- PMID: 12617873
- DOI: 10.1053/beha.2002.0226
New treatment strategies in childhood acute lymphoblastic leukaemia
Abstract
Today, 80% of paediatric patients with acute lymphoblastic leukaemia (ALL) can be cured. To reduce the rate of relapses, but also to limit treatment morbidity, risk-adapted treatment has been attempted after identifying the most specific prognostic factors. In addition to clinical factors (e.g. age, WBC), the immunophenotype and cytogenetic results, the early in vivo treatment response as determined by cytology had evolved as the most important predictor for relapse. The lack of specificity of most prognostic factors stimulated the search for more relevant parameters. Detection of minimal residual disease (MRD) at defined time points by identifying clone-specific T-cell receptor- (TCR) or immunoglobulin (Ig) gene rearrangements can provide new, highly specific prognostic information which allows definition of new risk groups. The high sensitivity of the method is a prerequisite for applying treatment reduction in patients with fast clearance of leukaemia. Persistent disease is an indication for treatment modification and intensification. Logistics and quality control are demanding but are essential for the introduction of this new technology into clinical practice.
Similar articles
-
Prognostic factors in childhood acute lymphoblastic leukemia.Indian J Pediatr. 2003 Oct;70(10):817-24. doi: 10.1007/BF02723806. Indian J Pediatr. 2003. PMID: 14649479 Clinical Trial.
-
Evolution of BFM trials for childhood ALL.Ann Hematol. 2004;83 Suppl 1:S121-3. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124702
-
Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.Br J Haematol. 2014 May;165(3):392-401. doi: 10.1111/bjh.12749. Epub 2014 Jan 30. Br J Haematol. 2014. PMID: 24479958 Clinical Trial.
-
Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.J Pediatr Hematol Oncol. 2001 Dec;23(9):591-7. doi: 10.1097/00043426-200112000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11902303 Review.
-
Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia.Baillieres Clin Haematol. 1994 Jun;7(2):183-233. doi: 10.1016/s0950-3536(05)80200-8. Baillieres Clin Haematol. 1994. PMID: 7803899 Review.
Cited by
-
Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS).Blood. 2011 Aug 4;118(5):1413-20. doi: 10.1182/blood-2011-01-331835. Epub 2011 Jun 7. Blood. 2011. PMID: 21652685 Free PMC article.
-
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.J Clin Invest. 2008 Sep;118(9):3132-42. doi: 10.1172/JCI35700. J Clin Invest. 2008. PMID: 18688285 Free PMC article. Clinical Trial.
-
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.Biol Blood Marrow Transplant. 2010 Sep;16(9):1187-211. doi: 10.1016/j.bbmt.2010.06.008. Epub 2010 Jun 14. Biol Blood Marrow Transplant. 2010. PMID: 20558311 Free PMC article.
-
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.Haematologica. 2009 Aug;94(8):1135-50. doi: 10.3324/haematol.2008.004267. Epub 2009 Jul 7. Haematologica. 2009. PMID: 19586938 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
